Study [reference] | Year of publication | SUV type | Subjects | Comments | Original threshold | SUV | SUV SQ | SUV AD | |
n1 | n2 | ||||||||
Agarwal et al. [34] | 2010 | Max. | 363 | 363 | Not included in previous meta-analysis | Median | 5.9 | 9.5 | 4.5 |
Borst et al. [16] | 2005 | Max. | 51 | 40 | Patients without histological confirmation were excluded | Median | 14.3 | 13.6 | 13.8 |
de Jong et al. [23] | 2007 | Max. | 66 | 66 | Median | 6.0 | 6.5 | 6.0 | |
Eschmann et al. [20] | 2006 | Mean | 159 | 136 | Primary author excluded patients with incomplete data | Best cut-off | 9.5 | 10.3 | 7.5 |
Goodgame et al. [27] | 2008 | Max. | 136 | 136 | Median | 5.5 | NR | NR | |
Higashi et al. [13] | 2002 | Mean | 57 | 48 | Primary author excluded patients | Best cut-off | 2.3 | 3.0 | |
Hoang et al. [29] | 2008 | Max./mean | 214 | 221 | Some patients were excluded in the original publication | Median | 11.1 | 13.9 | 9.2 |
Meert | Max. | 120 | 120 | Unpublished series# | Median | 11.7 | 18.7 | 9.9 | |
Port et al. [18] | 2005 | Max. | 64 | 64 | NR | 4.04 | 6.0 | 2.5 | |
Sasaki et al. [19] | 2005 | Max. | 162 | 162 | Best cut-off | 8.2 | 8.9 | 6.4 | |
van Baardwijk et al. [25] | 2007 | Max. | 46 | 46 | Best cut-off | 12.8 | 14.2 | 12.3 | |
Vansteenkiste et al. [11] | 1999 | Max. | 125 | 124 | One patient with SCLC was excluded | Best cut-off | 10.3 | 11.9 | 7.6 |
Data are presented as median, unless otherwise stated. SUV: standardised uptake value; n1: number of patients in the original publication; n2: number of patients included in the pooled analysis; SQ: squamous cell carcinoma; AD: adenocarcinoma; max.: maximum; NR: not reported; SCLC: small cell lung cancer. #: not included in previous meta-analysis.